ArticleScientific reports2025
Honokiol inhibits gastric cancer via tumor microenvironment modulation: a bioinformatics and single-cell analysis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Honokiol, a natural polyphenol from Magnolia bark, exhibits antitumor effects in various cancers. This study aimed to elucidate its pharmacological mechanisms in gastric cancer. Active components and their targets were retrieved from the Traditional Chinese Medicine Systems Pharmacology Database and SwissTargetPrediction databases. Gastric cancer-related genes were collected from the Comparative Toxicogenomics Database and GeneCards databases. Overlapping targets were analyzed using STRING to construct a protein-protein interaction network. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses were performed using DAVID and visualized using Cytoscape. Thirty-four overlapping targets were identified, with CHUK as a key hub gene. Functional enrichment analysis revealed multiple pathways, including NF-κB signaling. Single-cell analysis confirmed CHUK expression in tumor clusters, and immunohistochemistry validated its downregulation following honokiol treatment. These findings suggest that honokiol exerts multi-target and multi-pathway effects in gastric cancer, with CHUK-mediated inhibition of NF-κB signaling identified as a critical mechanism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.